Skip to main content
Find more clinical trials

LY3002813 for Mild Cognitive Impairment or Alzheimer's Disease

Start: December 2015
End: August 28, 2019
Enrollment: 150

What Is This Study About?

The study will evaluate the effect of the experimental drug LY3002813 in people with mild cognitive impairment (MCI) or mild to moderate Alzheimer's disease.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: N/A

Must have:

  • MCI due to Alzheimer's disease or mild-to-moderate Alzheimer's
  • For women, hysterectomy and/or bilateral oophorectomy, or no menstruation for at least 1 year
  • Caregiver/study informant who provides separate informed consent, is available by telephone at designated times, and will monitor administration of prescribed medications
  • Adequate vision and hearing for neuropsychological testing
  • Positive brain scan indicating Alzheimer's-related brain changes

Must NOT have:

  • Being monitored for radiation due to occupational exposure to ionized radiation, or exposure to ionizing radiation within last 12 months from an investigational study
  • History of intracranial hemorrhage, cerebrovascular aneurysm, arteriovenous malformation, carotid artery occlusion, stroke, or epilepsy
  • Contraindication for magnetic resonance imaging, including claustrophobia, metal (ferromagnetic) implants, or cardiac pacemaker
  • Allergies to humanized monoclonal antibodies, including proteins and diphenhydramine, epinephrine, and methylprednisolone
  • Have had gamma globulin therapy within the last year
  • Previous participation in any other study investigating active or passive immunization against amyloid-beta within the last 6 months
  • Current serious or unstable illness
 

Who Is the General Study Contact?

For more information about this trial, please contact Eli Lilly at 1-877-285-4559 Monday through Friday, 9 a.m. to 5 p.m. Eastern time. Refer to this study by its ClinicalTrials.gov identifier, NCT02624778.

Study Contact
Eli Lilly and Company
1-877-285-4559

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Florida
Brain Matters Research
Delray Beach, FL 33445
Compass Research
Orlando, FL 32806
Compass Research
The Villages, FL 32162
Maryland
SNBL Clinical Pharmacology Center Inc
Baltimore, MD 21201
Missouri
St. Louis Clinical Trials, LC
Saint Louis, MO 63141
Utah
PRA Health Sciences
Salt Lake City, UT 84106

Who Sponsors This Study?

Lead: Eli Lilly and Company

Source: ClinicalTrials.gov ID: NCT02624778